

13 August 2025

Oxford BioDynamics plc
("Oxford BioDynamics" or the "Company")

Oxford BioDynamics and Google Cloud Agree to Collaborate and Help Accelerate Cloud-Based Analytical Frameworks for Precision Medicine

Oxford, UK - 13 August 2025 - Oxford BioDynamics (OBD), a biotechnology company pioneering the use of 3D genomic biomarkers for clinical diagnostics, is pleased to announce that it is collaborating with **Google Cloud** to support the development and deployment of OBD's cutting-edge analytical framework on the cloud.

Through this collaboration, Google Cloud will provide support via cloud computing, enabling OBD to scale its proprietary **EpiSwitch® knowledge space and analytical tools** and deliver high-throughput, AI-powered 3D genomic analytics in a secure, efficient, and globally accessible environment to the benefit of its pharma and biotech partners. This effort marks an important milestone in OBD's digital transformation and utilisation of its knowledge base and reflects Google Cloud's commitment to empowering innovative life sciences research through its advanced cloud infrastructure.

Iain Ross, Executive Chairman of OBD said *"Working with Google Cloud allows OBD to rapidly scale its analytical capabilities, bringing it closer to delivering precision 3D genomics insights in real time. Since joining the company, I have been convinced of the value of our 3D Genomics knowledgebase and the formation of this collaboration with Google Cloud only serves to validate this view. We are excited to develop a powerful and interoperable platform that aligns with the future of cloud-native biomedical research. Google Cloud's global infrastructure allows us to share insights faster, collaborate more easily with our partners, and bring our predictive genomic tools into clinics and labs around the world - at scale."*

Background

OBD's growth trajectory across translational research, diagnostic development, and strategic partnerships is the key impetus for this collaboration with Google Cloud. The allocated resources will support containerized deployment, integration with Google Cloud's AI/ML tools, and secure, scalable data processing pipelines that meet healthcare compliance standards which will make the OBD platform more accessible to pharma and biotech companies and create future opportunities to commercialise the EpiSwitch platform.

OBD will provide access to its **EpiSwitch® platform**, a clinically validated technology that reveals regulatory 3D genome architecture changes, enabling the detection of complex disease signatures, disease understanding and target development.

OBD will work closely to monitor resource usage and performance benchmarks, ensuring a scalable and cost-effective model for ongoing innovation.

For further information please contact:

Oxford BioDynamics Plc

+44 (0)1865 518910

Iain Ross, Executive Chairman

Paul Stockdale, CFO

Shore Capital - Nominated Adviser and Broker

+44 (0)20 7408 4090

Advisory: Stephane Auton / Lucy Bowden

Broking: Fiona Conroy

Camarco - Financial PR

Marc Cohen / Tilly Butcher / Fergus Young

+44 (0)20 3757 4980

OBDfinancial@camarco.co.uk

Oxford BioDynamics Plc (AIM: OBD) is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use in clinical diagnostics and precision medicine. Its proprietary EpiSwitch® platform enables the detection of 3D genomic markers with wide applications in immuno-oncology, neurodegeneration, and pharmacogenomics

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEASPAFLNSEFA